Background. Type 2 diabetes is common, largely managed in primary care and requires effective glycaemic control to reduce the risk of microvascular complications. Oral hypoglycaemic agents are typically the first pharmacological intervention used to improve glycaemic control. Objectives. To evaluate the management of people with type 2 diabetes with oral hypoglycaemic agents in primary care.
Introduction
Type 2 diabetes is an increasingly common disease leading to micro-and macrovascular complications at significant cost to the National Health Service. [1] [2] [3] [4] Tight glycaemic control reduces microvascular complications and is cost effective but often not achieved. 5, 6 Most people with type 2 diabetes in the UK are managed entirely within primary care. 7 Treatment to control blood sugar typically comprises dietary advice with the addition of oral hypoglycaemic agents and/or insulin depending on subsequent glycaemic control measured by glycosylated haemoglobin levels (HbA 1c ). 8 The most commonly prescribed oral hypoglycaemic treatments are sulphonylureas and metformin, which may be used alone or in combination. In addition, newer 'third line' oral medications such as meglitinides and glitazones may be used. 8 As with hypertension and other clinical specialities there is evidence of clinical inertia in the management of diabetes. 9 Previous work from UK primary care has shown that glycaemic control is suboptimal for almost 40% of those with type 2 diabetes treated with medication. 10 A recent study using primary care data has shown that many people receiving dual therapy with both a sulphonylurea and metformin remain poorly controlled and do not subsequently receive more intensive treatment. 11 In North America, treatment with glucose-lowering agents appears to be delayed until HbA 1c levels are considerably above recommended targets in both primary and secondary care. 12, 13 This study sought to evaluate the management of type 2 diabetes based on retrospective analyses of UK primary care data from 1999 to 2003. Glycaemic monitoring and control were assessed in patients starting hypoglycaemic medication during the study period. Predictors of response to first therapy were assessed, and progression to and glycaemic control on second agents were evaluated.
Methods
Population Data were obtained from 243 general practices throughout England, Scotland and Wales providing continuous data to the DIN-LINK database over a 5-year period from 1999 to 2003. This database contains anonymized computer records from all patients registered with contributing practices which are similar to UK patients in terms of age and sex distribution.
14 Contributing practices are asked to record all patient contacts onto their electronic clinical system and diagnoses, investigations and prescriptions are coded using Read Codes. 15 Patients were identified with diabetes if they had a Read Code for diabetes or one or more prescriptions for oral antidiabetic agents, insulin or glucose testing kits. 16, 17 Patients were classified as having type 2 diabetes if they did not have a Read Code for gestational or type 1 diabetes or if they were prescribed an oral antidiabetic agent. Type 2 patients were classified as diet only if they had no prescription for an oral antidiabetic agent within the 5-year time frame.
Procedure and analyses
Analyses were performed using SAS V8.2 (SAS Institute, Cary, NC). The prevalence of type 2 diabetes was estimated based on people registered with type 2 diabetes on December 31, 2003. Time to first HbA 1c assessment was estimated for all patients who started their oral agent during the 5-year time period from the date of their first recorded prescription for an oral hypoglycaemic agent until their first recorded HbA 1c after the prescription. Patients who started a second agent were censored on the date of prescription and patients with no recorded HbA 1c were censored at the time of deregistration (if before the end of the study) or at the end of study.
Time to initiation of a second type of hypoglycaemic agent was estimated for all patients who started an oral agent during the 5-year time period from the date of their first prescription of a single agent until the date of prescription of a second agent. Patients who remained on a single agent were censored at the time of deregistration (if before the end of the study) or at the end of study.
The UK National Institute for Clinical Excellence guidance on the management of blood glucose for patients with type 2 diabetes, published in 2002, recommends that ' For each individual, a target HbA1c (DCCT aligned) should be set between 6.5% and 7.5%, based on the risk of macrovascular and microvascular complications.' 8 Adequate glycaemic control was therefore defined in this study as an HbA 1c < 7.5%. Glycaemic control after initiation of first or second therapy was evaluated based on all available HbA 1c results at 6-month intervals. Two separate models were used to assess the relationship between HbA 1c results in 3-6 months after starting metformin or sulphonylurea as first therapy, to pre-treatment HbA 1c , drug dose, ACORN geodemographic classification 18 (A Classification of Residential Neighbourhoods by postcodes, using census and lifestyle survey data) in 2001, age at first therapy, body mass index (BMI), gender, beta-blocker and diuretic use. These were evaluated using mixed models with an identity link, normal error and practice as a random effect (to account for any practice-related differences). A forward stepwise regression approach was used, with those variables identified as statistically significant in univariate analyses (P < 0.05) being entered into the final model until the addition of an extra variable was no longer significant. 19 To evaluate whether any of the variables had a non-linear relationship with outcome, we assessed transformations of each variable using the natural logarithm and cubic spline. 20 The Akaike Information Criteria (AIC) was used to determine the most appropriate transformation. 21 The effect of metformin daily dose was assessed in the following categories: <500 mg, >500 mg <1 g, >1 g <1.5 g or >1.5 g <3 g. Since sulphonylurea doses vary across the class, we assessed whether patients were receiving half of the recommended maximal dose as reported in the British National Formulary. 17 
Results
During the 5-year study period, 71 561 people with type 2 diabetes were identified, of these 54 731 remained registered on December 31, 2003 from a total population of 1.95 million, giving an overall prevalence of 2.8%. During the study, 50 406 (70.4%) received a prescription for an oral hypoglycaemic agent. For 20 922 patients, their first prescription of an oral agent (as opposed to diet alone) occurred during the study period, with 11 904 (57%) patients receiving metformin and 8839 (42%) a sulphonylurea. Patient demographics are shown with those prescribed metformin on average younger and with a higher BMI than those prescribed sulphonylureas (Table 1) . Metformin use as a first therapy has steadily increased over time, with 37% of patients receiving this as a first therapy in 1999 compared to 75% in 2003. A corresponding decrease in the use of sulphonylureas as initial therapy was observed, from 61% in 1999 to 25% in 2003. Very few patients ($1%) were prescribed other oral agents (meglitinides, glitazones or other therapies) as a first therapy.
HbA 1c assessment and control on first therapy
The median time to first HbA 1c following initiation of an oral agent was 0.51 years [95% confidence interval (CI) 0.50-0.53]. Time to event analysis revealed that 10 252 (49%) patients had a recorded HbA 1c within 6 months of starting therapy and 13 390 (64%) within the first year of therapy. In total, 5378 of 20 922 (26%) patients had a computer-recorded HbA 1c both in the 6 months before (mean 9.15%, SD 1.9%) and after (mean 7.57%, SD 1.3%) starting their first therapy. For patients prescribed metformin with available HbA 1c assessments (n = 3296), their mean HbA 1c prior to therapy was 9.1% (SD 1.8%) which fell to 7.7% (SD 1.3%) in the 6 months following the initiation of therapy. The mean HbA 1c prior to therapy for patients prescribed a sulphonylurea was slightly higher (mean 9.3%, SD 2.0%) which fell to 7.4% (SD 1.3%) post-therapy. Evaluation of all available HbA 1c results for patients at 6-monthly intervals showed that approximately 40% of patients on a single agent with available HbA 1c results were uncontrolled throughout the 5-year study period.
Patients initiating metformin in 2003 (n = 891) had slightly but significantly lower pre-treatment HbA 1c (mean 8.9%, SD 1.8%) than those initiating metformin earlier in the study (9.1%, SD 1.7%) (P = 0.004). Post-therapy mean HbA 1c was also lower in those initiating therapy in 2003 (mean 7.6%, SD 1.2%) compared to those prior to 2003 (mean 7.7%, SD 1.3%) (P = 0.058).
A non-significant decrease in pre-treatment HbA 1c was also observed in patients prescribed sulphonylureas with available results in 2003 (n = 273) (mean 2003 9.2%, SD 2.0% compared to a mean prior to 2003 of 9.3%, SD 2.0%; P = 0.23). Similar results were observed post-treatment (mean 7.39% both during and prior to 2003).
Prediction of response to first therapy in people with type 2 diabetes receiving metformin or sulphonylureas Analyses of the relationship between post-therapy HbA 1c (assessed 3-6 months after initiation) and (Table 2 ). BMI and beta-blocker/diuretic use were no longer significant in the final model but were correlated with age (beta-blocker/diuretic use was correlated with age, while BMI was inversely correlated with age). On average, greater reductions in HbA 1c were observed in older patients, those with a high pre-treatment HbA 1c , and those not classified as hardpressed or moderate means. 18 Assessment of interaction terms revealed a significant association between pre-treatment HbA 1c and metformin dose, with those patients with a higher pre-treatment HbA 1c prescribed higher doses (mean pre-treatment HbA 1c for those patients prescribed: <500 mg 8.4%; >500 mg <1 g 8.8%; >1 g <1.5 g 9.4%; >1.5 g <3 g 9.5%).
Analysis of the relationship between post-therapy HbA 1c and sulphonylureas (n = 1207) showed a significant association with pre-treatment HbA 1c, gender and dose, however, no association was observed with the remaining variables (Table 3 ). On average, female patients had a slightly higher HbA 1c following therapy. Univariate analyses clearly show that the decrease in HbA 1c is strongly associated with pre-treatment HbA 1c , with those patients with the highest pre-treatment HbA 1c experiencing the greatest reductions. The final model is more complex with sulphonylurea dose and the interaction between pre-treatment HbA 1c affecting outcome. Those patients with a high pre-treatment HbA 1c were more likely to be prescribed the half maximal recommended dose of sulphonylurea. Post hoc analysis of the effect of sulphonylurea category on post-therapy HbA 1c showed no significant differences between therapies compared to the most commonly prescribed sulphonylurea: glicazide.
Patient progression to and control on a second type of hypoglycaemic agent In total, 7009/20 922 (34%) patients were prescribed a second oral agent during the study; of these, 3022 (43%) received metformin, 2964 (42%) a sulphonylurea, 127 (2%) a meglitinide, 820 (12%) a glitazone and 76 (1%) other diabetes drugs or combination therapies. The median time from prescription of a first agent to prescription of a second agent was 3.86 years (95% CI 3.82-3.90). Only 2634 (38%) had HbA 1c assessments in both the 6 months before (mean 8.99%, SD 1.7%) and in the 6 months following therapy (mean 7.74%, SD 1.35). Of these patients, 1372 (52%) were uncontrolled post-therapy. Assessment of all available HbA 1c results at 6-month intervals for those patients remaining on a second agent revealed approximately 50% had poor glycaemic control (HbA 1c > 7.5%).
Discussion
Management of type 2 diabetes with oral hypoglycaemic agents appears to be suboptimal for many patients in UK Primary Care. For patients starting an oral agent during the study, both glycaemic monitoring and control were poor. Fewer than half of the patients had a computer-recorded HbA 1c within 6 months of starting therapy, and many patients had no recorded HbA 1c at 1 year. For those patients with available HbA 1c assessments, around 40% remained uncontrolled on a single agent. Evaluation of predictors of response to first therapy indicates that some patients with high pre-treatment HbA 1c are unlikely to be controlled by a single therapy even at high dose. Despite this, many patients remained on a single agent for long periods of time (median almost 4 years). Of those patients who did receive a second agent 50% remained poorly controlled following therapy. Our results clearly show that those patients with a high pre-treatment HbA 1c are more likely to receive higher doses of metformin or sulphonylureas and have the greatest decreases in HbA 1c in response to therapy. Our results also suggest older patients and those from less-deprived areas have decreased HbA 1c compared to younger patients and those from deprived areas when prescribed metformin. While male patients appear to have decreased HbA 1c compared to females prescribed sulphonylureas. These differences may reflect a difference in case mix of patients prescribed metformin versus sulphonylureas, their standard of care, patients' lifestyles or compliance to therapy. 22 The finding that those receiving metformin as their first oral hypoglycaemic agent were younger with a higher BMI than those receiving sulphonylureas is consistent with other findings from the UK. 23 It suggests preferential prescription of metformin to those with higher BMI while the younger age may reflect earlier failure of diet alone in the obese.
Population-based studies such as this depend on the quality of data used, careful diagnostic categorization and the ability to generalize from the results. The data suggest that many patients received suboptimal monitoring, however, this might reflect poor data recording, the use of self-monitoring or assessments taking place in secondary care. 24 The anonymized nature of the data means that it is not possible to cross check with paper records but some evidence suggests that electronic records may be more complete than manual records. 25 Some people may have been misclassified as having diabetes on the basis of prescribing data (for instance, those receiving metformin for polycystic ovary syndrome) but this is unlikely to have made much impact on the results, as judged by the similarity of the observed prevalence (2.8%) with data from another large-scale cross-sectional study of people with type 2 diabetes and also with the recently published prevalence figures from the Quality and Outcomes Framework. 10, 26 This study included all practices which contributed full data throughout the study period rather than applying data quality criteria. 27 The large population increases generalizability but may mean that actual performance has been underestimated if included practices have not electronically recorded all results. However, the inclusive methodology used mirrors the data collection for the new General Medical Services (GMS) contract and electronic coding by practices for diabetes has been shown to be better than in other conditions. 28 A further potential limitation of this study is that patients were evaluated only until the end of 2003. Practice may have changed in response to incorporation of National Institute of Clinical Excellence guidelines issued in 2002, which recommend HbA 1c assessments for people with type 2 diabetes at 2-to 6-monthly intervals and a target HbA 1c between 6.5% and 7.5%, and the new GMS contract, although the results presented are consistent with those from the first year of the new contract. 8, 26 It is encouraging that patients in 2003 were being prescribed oral agents at lower HbA 1c levels than those earlier in the study, although this may reflect differences in reporting. In the past, GPs may have been more likely to request or report HbA 1c where control was perceived to be poor.
Comparable work from the US suggests that the problems identified here are not confined to the UK: Brown and Nichols 12 evaluated patients receiving second-line therapy with metformin for people already receiving a sulphonylurea and found that mean HbA 1c prior to metformin was 9.4% and had been over 8% for many months. Shah et al. 13 found that fewer than half of patients with diabetes over 65 with high HbA 1c levels had intensification of treatment. Similarly in Europe, a Danish study including people with both type 1 and type 2 diabetes found the majority to be poorly controlled and French work suggests that less than 40% of people with type 2 diabetes have HbA 1c monitored. 29, 30 These poor results from daily practice are despite the clear advantages to patients from good glycaemic control in terms of reduction in complications. 5 The reasons for the observed suboptimal diabetes control are not clear from our data. Other work has suggested that clinical inertia is an important factor and that people with chronic disease are often reviewed without inadequate control being acted upon. 9 This may at least partly explain our data, in which case, more aggressive treatment with the earlier addition of insulin treatment may improve the situation. However, insulin alone is unlikely to be adequate: the UK Prospective Diabetes Study comparing initial treatment of type 2 diabetes with insulin or oral hypoglycaemics found that after 9 years of treatment, while more patients remained controlled on insulin monotherapy than oral agents, the majority of participants required multiple therapies whatever the initial agent. 31 Moreover, studies of adherence to medication suggest that average non-adherence rates in diabetes are approximately 25%. 32 Improving control may therefore require interventions at both physician and patient level.
In conclusion, patients with type 2 diabetes receive suboptimal monitoring and management of blood glucose levels. In order to achieve improved glycaemic control and meet national targets, such patients should receive more active monitoring of the progress of their diabetes and where appropriate progress more rapidly through the available treatment options. 6 Further research is required to assess the impact of clinical guidelines, incentives on HbA 1c monitoring and glycaemic control and to evaluate patient progression to and control on additional therapies such as insulin.
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